Product

The company has multiple preclinical and clinical programs in place, and pilot patient trials have been conducted with new technologies constantly in the pipeline. The lead program is in pre-clinical stage and focuses on the development of cell-based immunotherapies for viral infections. This program is in collaboration with National Taiwan University Hospital and is expected to enter Phase I/II trial in the end of 2008.

The second program is in pre-clinical stage and focuses on the development of a cell-based immunotherapy for cervical cancer caused by human papiloma virus (HPV). This program is in collaboration with Chang Gung Memorial Hospital in Taiwan and is expected to enter Phase I/II trial in in the end of 2008.

The 3rd is in Phase I/II clinical stage and focuses on the development of a cell-based immunotherapy for Epstein-Barr virus (EBV) and CMV infections. This program is in collaboration with Beijing Daopei Hospital.

The 4th is in Phase I/II clinical stage and focuses on the development of a cell-based immunotherapy for human herpes virus, and polyoma BK and JC virus. This program is in collaboration with Beijing Daopei Hospital.

The 5th is in Phase I/II clinical stage and focuses on the development of a cell-based immunotherapy for fungal infection, including Aspergillus, Candida and other fungi. This program is in collaboration with Beijing Daopei Hospital.

The 6th is in Phase I/IIclinical stage and focuses on the development of a mesenchymal stem cell (MSC) therapy for graft versus host disease (GvHD) commonly threatens hematopoietic post-transplant patients. This program is collaborated by Beijing Daopei Hospital.

The 7th is in Phase I/II clinical stage and focuses on the development of a cell-based immunotherapy for leukemia. This program is in collaboration with Beijing Daopei Hospital and the University of Florida.

The 8th is in pre-clinical stage and focuses on the development of an siRNA-based intra-cellular therapy for HIV/AIDS. This program is in collaboration with National Taiwan University Hospital.

The 9th is in pre-clinical stage and focuses on the development of a cell-based immunotherapy for breast cancer. This program is in collaboration with Tri-force General Hospital in Taiwan.